ArticleCellular & molecular biology letters2026
NK-cell-derived exosomes exert antitumor potency via miR-140/XYLT1/HSPG2 axis.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, necessitating novel therapies. This study investigated the therapeutic role of natural killer cell-derived exosomes (NK-Exo), whose antitumor mechanisms are incompletely understood. Exosomes were isolated from interleukin (IL)-2-independent NK-92MI cells via differential ultracentrifugation and characterized by nanoparticle tracking, electron microscopy, and western blotting. They exhibited cup-shaped morphology (50–150 nm), expressed CD81/TSG101, and demonstrated selective cytotoxicity against tumor cells (A549, A375) but not nontumor cells (293 T) in vitro; this effect was corroborated in patient-derived lung organoids. Small RNA sequencing revealed miR-140-3p as highly enriched in NK-Exo, and its expression correlated with improved survival in patients with NSCLC. Functional validation showed that overexpressing miR-140-3p enhanced NK-Exo cytotoxicity and directly inhibited cancer cell migration and invasion, whereas inhibiting miR-140-3p promoted tumor growth. Mechanistically, miR-140-3p directly targeted xylosyltransferase 1 (XYLT1), as confirmed by dual-luciferase assay, leading to reduced levels of heparan sulfate proteoglycan 2 (HSPG2). Knockdown of XYLT1 phenocopied the tumor-suppressive effects of miR-140-3p, while supplementation with heparan sulfate reversed them. In a Lewis lung carcinoma mouse model, intratumoral delivery of NK-Exo, miR-140-3p mimic, or XYLT1 Small interfering RNA (siRNA) significantly inhibited tumor growth and alleviated splenomegaly. In conclusion, NK-Exo deliver miR-140-3p to suppress tumors via the novel miR-140-3p/XYLT1/HSPG2 axis, presenting a promising therapeutic strategy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.